Total raised
$8.2M
Last: Undisclosed 2018-01
Stage
Mature
Founded
2004
Headcount
15
HQ
Rosh Haayin
Sector
Health Tech & Life Sciences
About
Beta-O2 Technologies is a biomedical company developing a proprietary implantable bioreactor, the Air, for the treatment of patients with type 1 diabetes. The Air is a small medical device that is implanted in a minimally invasive procedure. The device, which contains islets of Langerhans, is intended to free patients from insulin injections and continuous monitoring of glucose levels. The device also reduces the risk of hypoglycemic episodes and other complications of the condition. Because the Air device contains living cells, the patient needs to refill the air in the device using a replenishing device, which includes a dedicated injector.
Funding history · 5 rounds · $8.2M total
2018-01
Undisclosed
$25K
2017-09
Undisclosed
$200K
2015-03
Undisclosed
Undisclosed
2007-02
Undisclosed Round
Undisclosed
2004-03
Seed
$2.0M
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Beta-O2 Technologies' primary product?
- Beta-O2 Technologies developed a proprietary implantable bioreactor called 'the Air' for treating patients with type 1 diabetes.
- When was Beta-O2 Technologies founded?
- Beta-O2 Technologies was founded in January 2004.
- What is the current operational status of Beta-O2 Technologies?
- Beta-O2 Technologies is currently inactive, having ceased operations in August 2025.
- What was Beta-O2 Technologies' total funding raised?
- Beta-O2 Technologies raised a total of $8,225,000 USD.
- Which investors participated in Beta-O2 Technologies' Seed round in March 2004?
- In March 2004, SCP Vitalife and Heznek Fund invested in Beta-O2 Technologies' Seed round.
- Did Beta-O2 Technologies receive any grants?
- Yes, Beta-O2 Technologies received a grant of $1,000,000 USD from the IIA in September 2014.
- When did Beta-O2 Technologies begin human trials for its artificial pancreas?
- According to a March 2020 news report, Beta-O2 Technologies was set to begin human trials on its new artificial pancreas.
- What was the latest funding round for Beta-O2 Technologies?
- Beta-O2 Technologies' last recorded funding round was an Undisclosed Round in January 2018, with an amount of $25,000 USD from Sherpa InnoVentures.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyBiomaterials & Tissue EngineeringMedical DevicesMedical Treatment & Therapeutics
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesHealthcarePatientsProviders
Business model
B2B
Highlights
1 Patents
Tags
biotechnologyminimally-invasivediabetesmedical-devices